RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates
share
Excerpt
RVAC Medicines Pte. Ltd., an mRNA technology platform company launched by CBC Group in 2021 announced first-in-human study evaluating the business’s mRNA-based COVID-19 vaccine candidate, RVM-V001
Article Summary
RVAC Medicines Pte. Ltd., an mRNA technology platform company launched by CBC Group in 2021 announced first-in-human study evaluating the business’s mRNA-based COVID-19 vaccine candidate, RVM-V001
About 54 healthy adults in Australia will participate in an open-label, dose-escalation Phase 1 study to assess the safety and immunogenicity of RVM-V001
The objective of the study is to evaluate the portfolio of COVID-19 vaccine candidates offered by RVAC. This portfolio consists of three vaccine candidates: one against the ancestral strain, one against the Omicron strain, and one bivalent vaccination candidate combining elements of both strains.
In addition to the COVID-19 vaccine candidates, RVAC is creating further mRNA-based vaccines that specifically target infectious disorders such respiratory syncytial virus (RSV) and Clostridioides difficile infection (CDI). RVAC completed its Series B funding in April 2022, increasing the total amount raised by the business to US$ 170 million.
Comments
Leave A Comment
Leave a Reply
